Document:

<PAGE>
                                                                    Exhibit 10.1

                           AMICUS THERAPEUTICS, INC.

                           2002 EQUITY INCENTIVE PLAN

1.   Purpose.

     The purpose of this plan (the "Plan") is to secure for Amicus
Therapeutics, Inc. (the "Company") and its stockholders the benefits arising
from capital stock ownership by employees and members of the Board of Directors
of, and consultants and advisors to, the Company and any Parent Corporation, or
Subsidiary (each as defined in Section 14 hereof), who are expected to
contribute to the Company's future growth and success.

2.   Types of Awards and Administration.

     (a)  Types of Awards. Awards pursuant to this Plan shall be authorized by
action of the Board of Directors of the Company (or a Committee designated by
the Board of Directors) and may be (i) incentive stock options ("Incentive
Stock Options") to purchase shares of the Company's Common Stock, par value
$.01 per share ("Common Stock"), meeting the requirements of Section 422 of the
Internal Revenue Code of 1986, as amended (the "Code"), (ii) non-statutory
options to purchase shares of Common Stock, which are not intended to meet the
requirements of Code Section 422 ("Non-Statutory Stock Options" and, together
with Incentive Stock Options, "Options"), or (iii) shares of Common Stock
("Restricted Shares" and, together with "Options", "Awards").

     (b)  Administration. This Plan will be administered by the Board of
Directors of the Company, whose construction and interpretation of the terms
and provisions hereof shall be final and conclusive. The Board of Directors may
in its sole discretion make Awards and authorize the Company to issue shares of
Common Stock pursuant to such Awards, as provided in, and subject to the terms
and conditions of, this Plan. The Board of Directors shall have authority,
subject to the express provisions of this Plan, to construe this Plan and the
respective written agreements setting forth the terms and conditions of an
Award (each, an "Award Agreement"), to prescribe, amend and rescind rules and
regulations relating to this Plan, to determine the terms and provisions of
Award Agreements, which need not be identical, to advance the lapse of any
waiting, forfeiture or installment periods and exercise dates, and to make all
other determinations in the judgment of the Board of Directors necessary or
desirable for the administration of this Plan. The Board of Directors may
correct any defect or supply any omission or reconcile any inconsistency in
this Plan or in any Award Agreement in the manner and to the extent it shall
deem expedient to carry this Plan into effect and it shall be the sole and
final judge of such expediency. No director shall be liable for any action or
determination taken or made in good faith under or with respect to this Plan or
any Award.

     (c)  Delegation of Authority. The Board of Directors may, to the full
extent permitted by law, delegate any or all of its powers under this Plan to a
committee (the "Committee") of two or more directors, and if the Committee is
so appointed all references to the Board of Directors in this Plan shall mean
and relate to such Committee to the extent of the powers so delegated. The
Board of Directors may, from time to time, delegate to the Chief Executive
Officer authority
<PAGE>
under this Plan with respect to aggregate numbers of shares to permit specific
Awards by the Chief Executive Officer to employees and consultants of, and
advisors to, the Company, any Parent Corporation or any Subsidiary.

3.   Eligibility.

     Awards shall be made only to persons who are, at the time of grant,
officers, employees or directors of, or consultants or advisors to, (provided,
in the case of Incentive Stock Options, such directors or officers are then
also employees of) the Company or any Parent Corporation or Subsidiary. A
person who has been granted an Award may, if such person is otherwise eligible,
be granted an additional Award or Awards if the Board of Directors shall so
determine.

4.   Stock Subject to Plan.

     Subject to adjustment as provided in Sections 10 and 11 hereof, the
maximum number of shares of Common Stock of the Company which may be issued and
sold pursuant to Awards made under this Plan is 862,611 shares. Such shares may
be authorized and unissued shares or may be shares issued and thereafter
acquired by the Company. If either (i) Restricted Shares are forfeited
following their award under this Plan, or (ii) Options granted under this Plan
are canceled, or expire or terminate for any reason without having been
exercised in full, the forfeited Restricted Shares, or the unpurchased shares
of Common Stock subject to any such Option, as the case may be, shall again be
available for subsequent Awards under this Plan. Restricted Shares, Options and
shares of Common Stock issuable upon exercise of Options granted under this
Plan may be subject to transfer restrictions, repurchase rights or other
restrictions as shall be determined by the Board of Directors.

5.   Award Agreements.

     As a condition to the grant of an Award under this Plan, each recipient of
an Award shall sign an Award Agreement not inconsistent with this Plan in such
form, and providing for such terms and conditions, as the Board of Directors
shall determine at the time such Award is authorized to be granted. Such Award
Agreements need not be identical but shall comply with, and be subject to, the
terms and conditions set forth herein.

6.   Options Generally.

     (a)  Purchase Price. The purchase price per share of Common Stock
deliverable upon the exercise of (i) a Non-Statutory Stock Option may be less
than the fair market value of the Common Stock, and (ii) an Incentive Stock
Option may not be less than the fair market value of the Common Stock, as such
purchase price is determined by the Board of Directors on the date such Option
is authorized to be granted; provided, that in the event that the Common Stock
of the Company becomes registered under the Securities Exchange Act of 1934, as
amended (the "Exchange Act") and is publicly traded ("Publicly Traded"), the
fair market value of the Common Stock shall be equal to the closing price of
the Common Stock on the date such Option is authorized to be granted.

                                       2

<PAGE>
     (b)  Payment of Exercise Price. Payment of the exercise price of an Option
shall be in cash or, in the sole discretion of the Board of Directors, in shares
of capital stock of the Company held by the Option holder for greater than six
months, or by any other lawful means. The Company may, in its sole discretion,
make loans to an Option holder in an amount equal to all or part of the exercise
price of Options held by such Option holder which such loans may be secured or
unsecured, as agreed upon between the parties at such time; provided, that the
grant of a loan on any occasion to one or more Option holder(s) shall not
obligate the Company to grant loans on any other occasion or to such or any
other Option holder.

     (c)  Option Term. Each Option and all rights thereunder shall expire on
such date as the Board of Directors shall determine on the date such Option is
authorized to be granted, but in no event may any Option remain in effect after
the expiration of ten years from the day on which such Option is granted (or
five years in the case of Options described in paragraph (b) of Section 7
hereof), and such Option shall be subject to earlier termination as provided in
this Plan.

     (d)  Exercise of Options. Each Option shall be exercisable either in full
or in installments at such time or times and during such period as shall be set
forth in the Award Agreement evidencing such Option; provided, however, that,
(i) no Option shall have a term in excess of ten years from the date of grant
(or five years in the case of Options described in paragraph (b) of Section 7
hereof), and (ii) the periods of time following an Option holder's cessation of
employment with the Company, any Parent Corporation or Subsidiary, or service as
a consultant or advisor to the Company, any Parent Corporation or Subsidiary, or
following an Option holder's death or disability, during which an Option may be
exercised, as provided in paragraph (f) below, shall not be included for
purposes of determining the number of shares of Common Stock with respect to
which such Option may be exercised.

     (e)  Rights as a Stockholder. The holder of an Option shall have no rights
as a stockholder with respect to any shares covered by the Option until the date
of issue of a stock certificate to such person for such shares. Except as
otherwise expressly provided in the Plan, no adjustment shall be made for
dividends or other rights for which the record date is prior to the date such
stock certificate is issued.

     (f)  Effect of Cessation of Service. Notwithstanding anything contained in
this Plan to the contrary, no Option may be exercised unless, at the time of
such exercise, the recipient is, and has been continuously since the date of
grant of such recipient's Option, employed by or serving as a director,
consultant or an advisor to, one or more of the Company, a Parent Corporation or
a Subsidiary, except if and to the extent the applicable Award Agreement
provides otherwise (other than with respect to an Incentive Stock Option for
which Section 7 hereof shall apply); provided, however, that in no event may any
Option be exercised after the expiration date of the Option.

     (g)  Transfer Restrictions. Except as otherwise approved by the Board of
Directors, during the life of the holder thereof an Option shall be exercisable
only by or on behalf of such person and no Option granted under the Plan shall
be assignable or transferable by the person to whom it is granted, either
voluntarily or by operation of law, except by will or the laws of descent and
distribution.

                                       3

<PAGE>
     (h) Other Awards. Awards of Options may be made alone, in addition to or in
tandem with Awards of Restricted Shares under the Plan.

7.   Incentive Stock Options.

     Options granted under the Plan which are intended to be Incentive Stock
Options shall be specifically designated as Incentive Stock Options and shall be
subject to the following additional terms and conditions:

     (a)  Dollar Limitation. The aggregate fair market value (determined as of
the respective date or dates of the grant) of the Common Stock with respect to
which Incentive Stock Options granted to any employee under the Plan (and under
any other incentive stock option plans of the Company, and any Parent
Corporation and Subsidiary) are exercisable for the first time shall not exceed
$100,000 in any one calendar year. In the event that Section 422 of the Code is
amended to alter the limitation set forth therein so that following such
amendment such limitation shall differ from the limitation set forth in this
paragraph (a), the limitation of this paragraph (a) shall be automatically
adjusted accordingly.

     (b)  10% Stockholder. If any employee to whom an Incentive Stock Option is
to be granted under the Plan is at the time of the grant of such Option the
owner of stock possessing more than 10% of the total combined voting power of
all classes of stock of the Company or of any Parent Corporation or any
Subsidiary, then the following special provisions shall be applicable to the
Incentive Stock Option granted to such individual:

          (i)  the purchase price per share of Common Stock subject to such
     Incentive Stock Option shall not be less than 110% of the fair market value
     thereof at the time of grant; and

          (ii) the exercise period of such Incentive Stock Option shall not
     exceed five years from the date of grant.

Except as modified by the preceding provisions of this Section 7, all the
provisions of the Plan applicable to Options generally shall be applicable to
Incentive Stock Options granted hereunder.

     (c)  Effect of Cessation of Service. No Incentive Stock Option may be
exercised unless, at the time of such exercise, the holder of such Option is,
and has been continuously since the date of grant of such Incentive Stock
Option, employed by one or more of the Company, a Parent Corporation or
Subsidiary, except that if and to the extent the Award Agreement so provides:

          (i)  the Option may be exercised within the period of three months
     after the date the holder of an Option ceases to be employed by the
     Company, a Parent Corporation or a Subsidiary (or within such lesser period
     as may be specified in the Award Agreement) for any reason other than death
     or disability;

          (ii) if the holder of an Option dies while in the employ of the
     Company, a Parent Corporation or a Subsidiary or within three months after
     such holder ceases to be such an employee, the Option may be exercised by
     the person to whom it is transferred

                                       4

<PAGE>
     by will or the laws of descent and distribution within the period of one
     year after the date of death (or within such lesser period as may be
     specified in the Award Agreement); and

          (iii) if the holder of an Option becomes disabled (within the meaning
     of Section 22(e)(3) of the Code) while in the employ of the Company, a
     Parent Corporation or a Subsidiary, the Option may be exercised within the
     period of one year after the date the holder ceases to be an employee of
     any of the foregoing entities because of such disability (or within such
     lesser period as may be specified in the option agreement or instrument);

Except as modified by the preceding provisions of this Section 7, all the
provisions of the Plan shall be applicable to Incentive Stock Options granted
hereunder.

8.   Restricted Shares.

     (a)  Awards of Shares. Awards of Restricted Shares may be made under this
Plan on such terms and conditions as the Board of Directors may from time to
time approve. Awards of Restricted Shares may be made alone, in addition to or
in tandem with Awards of Options under this Plan. Subject to the terms of this
Plan, the Board of Directors shall determine the number of Restricted Shares to
be awarded to each recipient and the Board of Directors may impose different
terms and conditions on a Restricted Share Award than on any other Award made to
the same recipient or other Award recipients. Each recipient of Restricted
Shares shall, except in the circumstances described in paragraph (b) below, be
issued one or more stock certificates evidencing such Restricted Shares. Each
such certificate shall be registered in the name of such recipient, and shall
bear an appropriate legend referring to the terms and conditions applicable to
the Restricted Shares evidenced thereby.

     (b)  Forfeiture of Restricted Shares. In making an Award of Restricted
Shares, the Board of Directors may impose a requirement that the recipient must
remain in the employment or service (including service as an advisor or
consultant) of the Company or any Parent Corporation or Subsidiary for a
specified minimum period of time, or else forfeit all or a portion of such
Restricted Shares. In the case of a holder of Restricted Shares whose
relationship with the Company or any Parent Corporation or Subsidiary changes
during the term of any applicable forfeiture period in a manner that does not
constitute a complete separation therefrom (for example, from employee to
consultant or director, or vise versa), the Board of Directors shall have
authority to determine whether or not such change constitutes a cessation of
employment or service for purposes of such requirement. In such case, the
certificate(s) evidencing the Restricted Shares shall be held in custody by the
Company until such Shares are no longer subject to forfeiture.

     (c)  Rights as a Stockholder; Stock Dividends. Subject to any restrictions
set forth in the applicable Award Agreement, a recipient of Restricted Shares
shall have voting, dividend and all other rights of a stockholder of the Company
as of the date such Shares are issued and registered in recipient's name
(whether or not certificates evidencing such Shares are delivered to such
recipient). Except as may otherwise be set forth in the applicable Award
Agreement, stock dividends issued with respect to Restricted Shares shall be
treated as additional Restricted

                                       5

<PAGE>
Shares under the applicable Award Agreement and shall be subject to the same
terms and conditions that apply to the Restricted Shares with respect to which
such dividends are issued.

9.   General Award Restrictions.

     (a)  Investment Representations. The Company may require any person to
whom an Award is made, as a condition of such Award, to give written assurances
in substance and form satisfactory to the Company to the effect that such
person is acquiring the Common Stock subject to the Award for such person's own
account for investment and not with any present intention of selling or
otherwise distributing the same, and to such other effects as the Company deems
necessary or appropriate in order to comply with applicable Federal and State
securities laws.

     (b)  Special Conditions to Issuance of Shares. Each Award shall be subject
to the requirement that, if at any time counsel to the Company shall determine
that the listing, registration or qualification of the shares of Common Stock
subject to such Award upon any securities exchange or under any State or
Federal law, or the consent or approval of any governmental or regulatory body,
is necessary as a condition of, or in connection with, the issuance or purchase
of such shares thereunder, such shares may not be issued unless such listing,
registration, qualification, consent or approval shall have been effected or
obtained on conditions acceptable to the Board of Directors. Nothing herein
shall be deemed to require the Company to apply for or to obtain such listing,
registration or qualification.

10.  Recapitalization.

     In the event that the outstanding shares of Common Stock of the Company
are changed into or exchanged for a different number or kind of shares or other
securities of the Company by reason of any recapitalization, reclassification,
stock split, stock dividend, combination or subdivision, appropriate adjustment
shall be made in the number and kind of shares available under this Plan and
under any Options granted under this Plan. Such adjustment to outstanding
Options shall be made without change in the total exercise price applicable to
the unexercised portion of such Options, but a corresponding adjustment in the
applicable Option exercise price per share shall be made. No such adjustment
shall be made which would, within the meaning of any applicable provisions of
the Code, constitute a modification, extension or renewal of any Option or a
grant of additional benefits to the holder of an Option.

11.  Reorganization of the Company.

     In case (i) of any consolidation or merger involving the Company if the
shareholders of the Company immediately before such merger or consolidation do
not own, directly or indirectly, immediately following such merger or
consolidation, more than fifty percent (50%) of the combined voting power of
the outstanding voting securities of the corporation resulting from such merger
or consolidation in substantially the same proportion as their ownership of the
outstanding voting securities of the Company immediately before such merger or
consolidation; (ii) of any sale, lease, license, exchange or other transfer (in
one transaction or a series of related transactions) of all, or substantially
all, of the business and/or assets of the Company; or (iii) any person (as such
term is used in Sections 13(d) and 14(d) of the Exchange Act) shall become

                                       6

<PAGE>
(x) the beneficial owner (within the meaning of Rule 13d-3 under the Exchange
Act) of over 50% of the combined voting power of the Company's then outstanding
voting securities entitled to vote generally or (y) a "controlling person" (as
defined in Rule 405 under the Securities Act of 1933, as amended) (a
"Controlling Person") of the Company (each of the events described in the
foregoing clauses (i), (ii) and (iii), a "Reorganization Event"), the Board of
Directors of the Company, or the board of directors of any corporation assuming
the obligations of the Company, shall, as to outstanding Options, either (x)
make appropriate provision for the protection of any such outstanding Options
by the substitution on an equitable basis of appropriate stock of the Company,
or of the merged, consolidated or otherwise reorganized corporation which will
be issuable in respect of the shares of Common Stock of the Company, provided
that no additional benefits shall be conferred upon holders of Options as a
result of such substitution, and the excess of the aggregate fair market value
of the shares subject to any Option immediately after such substitution over
the purchase price thereof is not more than the excess of the aggregate fair
market value of the shares subject to such Option immediately before such
substitution over the purchase price thereof, or (y) upon written notice to the
holders of Options, provide that all unexercised Options must be exercised
within a specified number of days of the date of such notice or they will be
terminated. In any such case, the Board of Directors may, in its discretion,
accelerate the exercise dates of outstanding Options, and the vesting dates of
any Restricted Shares subject to forfeiture.

12. No Special Employment Rights.

     Nothing contained in this Plan or in any Award Agreement shall confer upon
any Award recipient any right with respect to the continuation of such person's
employment by the Company (or any Parent Corporation or Subsidiary) or
interfere in any way with the right of the Company (or any Parent Corporation
or Subsidiary), subject to the terms of any separate agreement to the contrary,
at any time to terminate such employment or to increase or decrease the
compensation of the Award recipient from the rate in existence at the time of
the Award. Whether an authorized leave of absence, or absence in military or
government service, shall constitute termination or cessation of employment for
purposes of this Plan or any Award shall be determined by the Board of
Directors.

13. Other Employee Benefits.

     The amount of any compensation deemed to be received by an employee as a
result of any Award (including the exercise of an Option, or the sale of shares
of Common Stock received upon such exercise or of Restricted Shares) will not
constitute "earnings" with respect to which any other employee benefits of such
employee are determined, including without limitation benefits under any
pension, profit sharing, life insurance or salary continuation plan.

14. Definitions.

     (a)  Subsidiary. The term "Subsidiary" as used in this Plan shall mean any
corporation in an unbroken chain of corporations beginning with the Company if
each of the corporations other than the last corporation in the unbroken chain
owns stock possessing 50% or more of the total combined voting power of all
classes of stock in one of the other corporations in such chain. For purposes
only of Awards of Non-Statutory Options or Restricted Shares, the

                                       7
<PAGE>
term "Subsidiary" shall also mean any partnership or limited partnership of
which the Company or any Subsidiary controls 50% or more of the voting power, or
any corporation in an unbroken chain of Subsidiaries if each of the Subsidiaries
other than the last Subsidiary in the unbroken chain either owns stock
possessing 50% or more of the total combined voting power of all classes of
stock in one of the other corporations or controls 50% or more of the voting
power of any such partnership or limited partnership in such chain.

     (b)  Parent Corporation. The term "Parent Corporation" as used in this Plan
shall mean any corporation (other than the Company) in an unbroken chain of
corporations ending with the Company if each of the corporations other than the
Company owns stock possessing 50% or more of the combined voting power of all
classes of stock in one of the other corporations in such chain.

     (c)  Employment. The term "employment", as used in this Plan and in any
Award Agreement, shall, unless the context otherwise requires, be defined in
accordance with the provisions of Section 1.421-7(h) of the Federal Income Tax
Regulations (or any successor regulations).

15.  Amendment of this Plan.

     The Board of Directors may at any time and from time to time modify, amend
or terminate this Plan in any respect, except to the extent stockholder approval
is required by law. The termination or any modification or amendment of this
Plan shall not, without the consent of an Award recipient, adversely affect such
Award recipient's rights under any Award Agreement unless such Agreement so
specifies. With the consent of the Award recipient affected, the Board of
Directors may amend outstanding Award Agreements in a manner not inconsistent
with this Plan. The Board of Directors shall have the right to amend or modify
the terms and provisions of this Plan and of any outstanding Incentive Stock
Options granted under this Plan to the extent necessary to qualify any or all
such Options for such favorable Federal income tax treatment (including deferral
of taxation upon exercise) as may be afforded incentive stock options under
Section 422 of the Code.

16.  Withholding.

     The Company's obligation to deliver Restricted Shares awarded, or shares
deliverable upon the exercise of any Option granted, under this Plan shall be
subject to the Award recipient's satisfaction of all applicable Federal, State
and local income and employment tax withholding requirements, and the Award
recipient shall elect to withhold only the minimum statutory taxes.

17.  Duration of this Plan.

     Unless earlier terminated by the Board of Directors, this Plan shall
terminate upon the earlier of (i) the close of business on April 22, 2012 or
(ii) the date on which all shares available for issuance under this Plan shall
have been issued as Restricted Shares or pursuant to the exercise of Options
granted under this Plan and/or are no longer subject to forfeiture pursuant to
the terms of any applicable Award Agreement. If the date of termination is
determined under

                                       8

<PAGE>
(i) above, then Awards outstanding on such date shall continue to have force and
effect in accordance with the provisions of the Award Agreements evidencing such
Awards.

                                        Adopted on April 22, 2002 by the
                                        Board of Directors and approved by
                                        stockholders on July 30, 2002.

                                       9
<PAGE>

THE FOLLOWING RESOLUTIONS WERE ADOPTED AT A MEETING OF THE BOARD OF DIRECTORS OF
AMICUS THERAPEUTICS, INC. ON FEBRUARY 28, 2006:

Stock Option Plan

     RESOLVED, that the Company's 2002 Equity Incentive Plan (the "Plan") be
amended by increasing the number of shares of Common Stock issuable under the
Plan to employees, officers, directors, consultants and agents of the Company to
17,500,000 shares; and be it further

     RESOLVED, that the Company hereby reserve a total of 17,500,000 shares of
Common Stock for issuance under the Plan; and be it further
<PAGE>
                          AMICUS THERAPEUTICS, INC.

                                 AMENDMENT TO
                          2002 EQUITY INCENTIVE PLAN

                                 AUGUST 2006

      The 2002 Equity Incentive Plan of Amicus Therapeutics, Inc., as amended
(the "Plan"), shall be further amended as set forth herein. Except to the extent
specifically amended as set forth herein, the Plan shall remain in full force
and effect. All capitalized terms used herein without definition shall have the
definitions for such terms as set forth in the Plan.

      1.    Section 3 of the Plan is amended by adding the following sentence at
the end of the paragraph:

            "Further, in no event shall the number of shares of Common Stock
            covered by Awards granted to any one person in any one calendar year
            (or portion of a year) ending after such date exceed twenty-five
            percent (25%) of the aggregate number of shares of Common Stock
            subject to this Plan."

      2.    As amended in February 2006, the first sentence of Section 4 of the
Plan now reads as follows (based upon the capitalization of the Company as of
May 8, 2006):

            "Subject to adjustment as provided in Sections 10 and 11 hereof, the
            maximum number of shares of Common Stock of the Company which may be
            issued and sold pursuant to Awards (including pursuant to Incentive
            Stock Options) made under this Plan is 17,500,000 shares." (emphasis
            added)

      3.    Section 6 of the Plan is amended by adding the following phrase at
the end of the last sentence thereof:

            "or, if no closing price is reported for that date, the closing
            price on the next preceding date for which a closing price was
            reported."

      4.    Section 9 of the Plan is amended by adding the following provisions
after subsection (b) thereof:

            "(c) Violation of Law. Notwithstanding any other provision of the
            Plan or the relevant Award Agreement, if, at any time, in the
            reasonable opinion of the Company, the issuance of shares of Common
            Stock covered by an Award may constitute a violation of law, then
            the Company may delay such issuance and the delivery of a
            certificate for such shares until (i) approval shall have been
            obtained from such governmental agencies, other than the Securities
            and Exchange Commission, as may be required under any applicable
            law, rule, or regulation and (ii) in the case where such issuance
            would constitute a violation of a law

<PAGE>

            administered by or a regulation of the Securities and Exchange
            Commission, one of the following conditions shall have been
            satisfied:

                  (A) the shares are at the time of the issue of such shares
                  effectively registered under the Securities Act; or

                  (B) the Company shall have determined, on such basis as it
                  deems appropriate (including an opinion of counsel in form and
                  substance satisfactory to the Company) that the sale,
                  transfer, assignment, pledge, encumbrance or other disposition
                  of such shares or such beneficial interest, as the case may
                  be, does not require registration under the Securities Act or
                  any applicable state securities laws.

            (d) Corporate Restrictions on Rights in Stock. Any Common Stock to
            be issued pursuant to Awards granted under the Plan shall be subject
            to all restrictions upon the transfer thereof which may be now or
            hereafter imposed by the Certificate of Incorporation and the
            By-laws of the Company, each as amended and in effect from time to
            time. Whenever Common Stock is to be issued pursuant to an Award, if
            the Committee so directs at the time of grant (or, if such Award is
            an Option, at any time prior to the exercise thereof), the Company
            shall be under no obligation, notwithstanding any other provision of
            the Plan or the relevant Award Agreement to the contrary, to issue
            such shares until such time, if ever, as the recipient of the Award
            (and any person who exercises any Option, in whole or in part),
            shall have become a party to and bound by any agreement that the
            Committee shall require in its sole discretion. In addition, any
            Common Stock to be issued pursuant to Awards granted under the Plan
            shall be subject to all stop-transfer orders and other restrictions
            as the Committee may deem advisable under the rules, regulations and
            other requirements of any stock exchange upon which the Common Stock
            is then listed, and any applicable federal or state securities laws,
            and the Committee may cause a legend or legends to be put on any
            such certificates to make appropriate reference to such
            restrictions.

            (e) Investment Representations. The Company shall be under no
            obligation to issue any shares covered by an Award unless the shares
            to be issued pursuant to Awards granted under the Plan have been
            effectively registered under the Securities Act or the holder of
            such Award shall have made such written representations to the
            Company (upon which the Company believes it may reasonably rely) as
            the Company may deem necessary or appropriate for purposes of
            confirming that the issuance of such shares will be exempt from the
            registration requirements of that Act and any applicable state
            securities laws and otherwise in compliance with all applicable
            laws, rules and regulations, including but not limited to that the
            holder of such Award is acquiring shares for his or her own account
            for the purpose of investment and not with a view to, or for sale in
            connection with, the distribution of any such shares.

            (f) Registration. If the Company shall deem it necessary or
            desirable to register under the Securities Act or other applicable
            statutes any shares of Common Stock issued or to be issued pursuant
            to Awards granted under the Plan, or to qualify any such shares of
            Common Stock for exemption from the Securities Act or other
            applicable statutes, then the Company shall take such action at its
            own expense. The Company may require from each recipient of an
<PAGE>
            Award, or each holder of shares of Common Stock acquired pursuant to
            the Plan, such information in writing for use in any registration
            statement, prospectus, preliminary prospectus or offering circular
            as is reasonably necessary for such purpose and may require
            reasonable indemnity to the Company and its officers and directors
            from such holder against all losses, claims, damage and liabilities
            arising from such use of the information so furnished and caused by
            any untrue statement of any material fact therein or caused by the
            omission to state a material fact required to be stated therein or
            necessary to make the statements therein not misleading in the light
            of the circumstances under which they were made.

            (g) Lock-Up. Without the prior written consent of the Company or the
            managing underwriter in any public offering of shares of Common
            Stock, no holder of an Award shall sell, make any short sale of,
            loan, grant any option for the purchase of, pledge or otherwise
            encumber, or otherwise dispose of, any shares of Common Stock during
            the one hundred-eighty (180) day period commencing on the effective
            date of the registration statement relating to any underwritten
            public offering of securities of the Company. The foregoing
            restrictions are intended and shall be construed so as to preclude
            any holder of an Award from engaging in any hedging or other
            transaction that is designed to or reasonably could be expected to
            lead to or result in, a sale or disposition of any shares of Common
            Stock during such period even if such shares of Common Stock are or
            would be disposed of by someone other than such holder. Such
            prohibited hedging or other transactions would include, without
            limitation, any short sale (whether or not against the box) or any
            purchase, sale or grant of any right (including without limitation
            any put or call option) with respect to any shares of Common Stock
            or with respect to any security that includes, relates to, or
            derives any significant part of its value from any shares of Common
            Stock. Without limiting the generality of the foregoing provisions
            of this Section 9.5, if, in connection with any underwritten public
            offering of securities of the Company, the managing underwriter of
            such offering requires that the Company's directors and officers
            enter into a lock-up agreement containing provisions that are more
            restrictive than the provisions set forth in the preceding sentence,
            then (a) each holder (regardless of whether or not such holder has
            complied or complies with the provisions of clause (b) below) shall
            be bound by, and shall be deemed to have agreed to, the same lock-up
            terms as those to which the Company's directors and officers are
            required to adhere; and (b) at the request of the Company or such
            managing underwriter, each holder shall execute and deliver a
            lock-up agreement in form and substance equivalent to that which is
            required to be executed by the Company's directors and officers.

            (h) Placement of Legends; Stop Orders; Etc. Each share of Common
            Stock to be issued pursuant to Awards granted under the Plan may
            bear a reference to the investment representations made in
            accordance with Section 9.3 in addition to any other applicable
            restrictions under the Plan, the terms of the Award and, if
            applicable, under any agreement between the Company and any Optionee
            and/or holder, and to the fact that no registration statement has
            been filed with the Securities and Exchange Commission in respect to
            such shares of Common Stock. All certificates for shares of Common
            Stock or other securities delivered under the Plan shall be subject
            to such stock transfer orders and other restrictions as the
            Committee may deem advisable under the rules, regulations, and other
<PAGE>
            requirements of any stock exchange upon which the Common Stock is
            then listed, and any applicable federal or state securities law, and
            the Committee may cause a legend or legends to be placed on any such
            certificates to make appropriate reference to such restrictions.

            (i) Tax Withholding. Whenever shares of Common Stock are issued or
            to be issued pursuant to Awards granted under the Plan, the Company
            shall have the right to require the recipient to remit to the
            Company an amount sufficient to satisfy federal, state, local or
            other withholding tax requirements if, when, and to the extent
            required by law (whether so required to secure for the Company an
            otherwise available tax deduction or otherwise) prior to the
            delivery of any certificate or certificates for such shares. The
            obligations of the Company under the Plan shall be conditional on
            satisfaction of all such withholding obligations and the Company
            shall, to the extent permitted by law, have the right to deduct any
            such taxes from any payment of any kind otherwise due to the
            recipient of an Award. However, in such cases holders may elect,
            subject to approval of the Committee, acting in its sole discretion,
            to satisfy an applicable withholding requirement, in whole or in
            part, by having the Company withhold shares to satisfy their tax
            obligations.

      5.    Section 15 of the Plan is amended by adding the following sentence
after the second sentence thereof:

            "Subject to the foregoing, this Plan may be terminated, amended or
            modified by the board of directors, and such termination, amendment
            and/or modification shall apply to and govern each then outstanding
            Award under this Plan."

<PAGE>
THE FOLLOWING RESOLUTIONS WERE ADOPTED BY WRITTEN CONSENT OF THE BOARD OF
DIRECTORS OF AMICUS THERAPEUTICS, INC. ON SEPTEMBER 13, 2006:

                   Amendment of 2002 Equity Incentive Plan

            RESOLVED, that effective upon the initial closing of the
transactions contemplated by the Transaction Documents (the "Initial Closing"),
the 2002 Equity Incentive Plan (the "Plan") is hereby amended to increase the
number of shares of Common Stock available for issuance thereunder to 20,500,000
shares of Common Stock; and be it further

            RESOLVED, that the Designated Officers be, and each hereby is,
authorized and directed to solicit and obtain the approval of the stockholders
to such amendment of the Plan, and to take such further actions as are necessary
to effect the amendment to the Plan; and be it further

            RESOLVED, that the Company hereby reserves a total of 20,500,000
shares of Common Stock for issuance under the Plan; and be it further<PAGE>

                                                                    Exhibit 10.3

                                                                  EXECUTION COPY

                                    AGREEMENT

                                     BETWEEN

                        MOUNT SINAI SCHOOL OF MEDICINE OF
                               NEW YORK UNIVERSITY

                                       AND

                            AMICUS THERAPEUTICS, INC.

LICENSE AGREEMENT

This License Agreement (the "Agreement") is made and effective as of April 15,
2002 (the "Effective Date"), by and between:

MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, a corporation organized
and existing under the laws of the State of New York and having a place of
business at One Gustave L. Levy Place, New York, NY 10029 ("MSSM")

AND

Amicus Therapeutics, Inc., a corporation duly organized and existing under the
laws of Delaware, and having its principal office at 1055 Washington Blvd.,
Stamford, Connecticut 06901, c/o CHL Medical Partners, L.P. ("AMICUS").

RECITALS

WHEREAS:

MSSM has an ownership interest in certain Patent Rights (as hereinafter
defined); and

AMICUS wishes to obtain a license to manufacture, use, sell and offer for sale
the products covered by the Patent Rights and MSSM desires to grant such
license, all on the terms and conditions set forth herein.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
<PAGE>

NOW, THEREFORE, IT IS HEREBY DECLARED AND AGREED BETWEEN THE PARTIES AS FOLLOWS:

1.   Definitions.

Whenever used in this Agreement, the following terms shall have the following
meanings:

     a.   "Affiliate" shall mean any corporation, firm, limited liability
          company, partnership or other entity that directly or indirectly
          controls or is controlled by or is under common control with a party
          to this Agreement. "Control" means ownership, directly or through one
          or more Affiliates, of 50 percent or more of the shares of stock
          entitled to vote for the election of directors, in the case of a
          corporation, or 50 percent or more of the equity interests in the case
          of any other type of legal entity, status as a general partner in any
          partnership, or any other arrangement whereby a party controls or has
          the right to control the board of directors or equivalent governing
          body of a corporation or other entity.

     b.   "Calendar Year" shall mean any consecutive period of twelve months
          commencing on the first day of January of any year.

     c.   "Chaperones" shall mean compounds that improve protein folding,
          stability or sorting or decrease protein degradation.

     d.   "Conformational Diseases" shall mean any human disease in which at
          least a sub-population of the affected individuals have a mutant
          protein that results in impaired protein folding, stability,
          degradation or sorting.

     e.   "Field" shall mean the discovery, validation, development,
          application, production or sale of Licensed Products: (i) for the
          prevention, diagnosis and treatment of Conformational Diseases (ii)
          that are Chaperones to improve the production and/or manufacturing of
          therapeutic proteins for the treatment of Conformational Diseases that
          are manufactured and sold by third parties, (iii) that are Chaperones
          discovered and developed by AMICUS to improve the production and/or
          manufacturing of therapeutic proteins for the treatment of diseases
          other than Conformational Diseases that are manufactured and sold by
          third parties, or (iv) that are Chaperones discovered and developed by
          Amicus for co-administration with therapeutic proteins for the
          treatment of disease other than Conformational Diseases that are
          manufactured and sold by third parties.

     f.   "License" shall mean the license under the Patent Rights to develop,
          manufacture, have manufactured, use, offer for sale and sell the
          Licensed Products as provided in Article 2, below.

     g.   "Licensed Product" shall mean any product or part thereof, the
          manufacture, use, or sale of which is: (i) covered by one or more
          Valid Claims of any Patent Rights, or (ii) which could not be
          developed, manufactured, used, sold, comprised or delivered without
          the Patent Rights.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        2

<PAGE>

     h.   "Net Sales" shall mean the total amount invoiced by AMICUS or by any
          AMICUS Affiliate or sub-licensee of AMICUS in connection with sales to
          any purchaser of the Licensed Products that is not an Affiliate or a
          sub-licensee of AMICUS or an AMICUS Affiliate, after deduction of all
          the following to the extent applicable to such sales;

          i)   trade, cash and quantity credits, discounts, refunds or rebates;

          ii)  allowances or credits for returns;

          iii) sales commissions;

          iv)  sales taxes (including value added tax), and

          v)   freight and insurance charges borne by the seller.

      i.  "Patent Rights" shall mean any issued patent or any patent to be
          issued pursuant to any United States or foreign patent application
          owned, by MSSM, listed in this subclause 1.i.(i)-(v) together with any
          continuations in whole or in part, divisional or substitute patents,
          any reissues or re-examinations of any such application or patents,
          and any extension of the term of any such patent in the Field. The
          issued patents and patent applications referred to in the preceding
          sentence are:

               i)   U.S. Pat. No. 6,274,597- "Method of Enhancing Lysosomal
                    AlphaGalA";

               ii)  U.S. Pat. Applic. No. 09/604,053 (continuation in part) -
                    "Method of Enhancing Mutant enzyme activities in lysosomal
                    storage disease";

               iii) U.S. Pat. Applic. No. 09/926,285 (continuation of the '597
                    Patent; and

               iv)  U.S. Pat. Applic. No. 09/948,348 (continuation of the '053
                    CIP Application.

               v)   U.S. Pat. Applic. entitled "Screen for active site specific
                    chaperones for enhancing protein folding of mutant proteins"
                    filed on March 1, 2002.

     j.   "Valid Claim" shall mean a claim of (i) an issued patent included in
          the Patent Rights which has not been declared invalid in a final,
          unappealable decision of a court of appropriate jurisdiction, or (ii)
          a pending patent application included in the Patent Rights which is
          being diligently prosecuted by or on behalf of MSSM and has not been
          formally terminated or abandoned without issuance of a patent.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        3

<PAGE>

2.   The License

     a.   Subject to the terms and conditions hereinafter set forth, MSSM hereby
          grants to AMICUS and AMICUS hereby accepts from MSSM the world-wide
          right under the Patent Rights to develop Licensed Products for use in
          the Field and to manufacture, use, sell and offer for sale the
          Licensed Products for use in the Field. Except as set forth in Section
          2e and 8f the License shall be exclusive as to all rights of MSSM in
          and to the Patent Rights. During the term of this Agreement, MSSM
          shall make no further grant of rights in and to the Patent Rights
          inconsistent with the rights of AMICUS herein.

     b.   AMICUS shall be entitled to grant sub-licenses under the License on
          terms and conditions not inconsistent with this Agreement (except that
          the rate of royalty may be at higher rates than those set forth in
          this Agreement): (i) to an Affiliate, and (ii) to other third parties
          for consideration and in arms-length transactions.

     c.   All sub-licenses shall only be granted by AMICUS pursuant to a written
          agreement, a true and complete copy of which shall be submitted by
          AMICUS to MSSM as soon as practicable after the signing thereof. Each
          sub-license granted by AMICUS hereunder shall be subject and
          subordinate to the terms and conditions of this License Agreement and
          shall contain, inter alia, the following provisions:

          i)   the sub-license shall expire automatically on the termination of
               the License;

          ii)  the sub-license shall not be assignable, in whole or in part;

          iii) the sub-licensee shall not be entitled to grant further
               sub-licenses; and

          iv)  both during the term of the sub-license and thereafter the
               sub-licensee shall be bound by a secrecy obligation similar to
               that imposed on AMICUS in Section 6 below, and that the
               sub-licensee shall bind its employees and agents, both during the
               terms of their employment and thereafter, with a similar
               undertaking of secrecy.

     d.   The sub-license agreement shall also include the text of Sections 6, 9
          and 10 of this Agreement and shall state that MSSM is an intended
          third party beneficiary of such sub-license agreement for purposes of
          enforcing such indemnification and insurance provisions.

     e.   The License shall be subject to (i) a non-exclusive license in favor
          of the U.S. Government to the extent required by Title 35 U.S.C.A.
          Section 200 et seq., or as otherwise required by virtue of use of
          federal funding in support of inventions claimed within the Patent
          Rights and (ii) a right and license retained by MSSM on behalf of
          itself and its faculty, students and academic collaborators to
          practice the Patent Rights for its own bona fide research, including
          sponsored research and collaborations. The retained rights granted in
          this Section 2e shall not give

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        4

<PAGE>

          MSSM the right to offer or grant rights in the Field under the Patent
          Rights to third parties.

     f.   Except for the License expressly provided in this Section 2, neither
          party hereto will, as a result of this Agreement, obtain any ownership
          interest in, or any other right or license to, any existing
          technology, patents, or Confidential Information, as defined in
          Section 6, below, of the other party.

3.   Royalty

     a.   In consideration for the grant of the License hereunder, subject to
          the provisions of Section 3.b, (i) AMICUS shall pay to MSSM [***] on
          Net Sales; and (ii) in the event AMICUS grants sublicenses with
          respect to any Licensed Product pursuant to which AMICUS receives
          remuneration other than royalties, then AMICUS shall pay to MSSM [***]
          of all payments that AMICUS receives from such sublicensee or other
          parties, including, without limitation: (a) Contract Signature
          Payments, (b) Third Party Milestone Payments, or (c) Maintenance Fees.

          As used in this Section 3.a.(ii), the term "Contract Signature
          Payment" means license initiation fees and all other up-front
          payments made to AMICUS in connection with a sublicense or similar
          agreement; "Third Party Milestone Payments" means payments made to
          AMICUS upon fulfillment by AMICUS or the sub-licensee of designated
          development objectives or regulatory requirements; and "Maintenance
          Fees" means payments (such as annual minimum royalties) made by
          sub-licensees to AMICUS to preserve, or to avoid a forfeiture of
          rights under, the sublicense agreement;

          With respect to any sublicensing or other transaction to which this
          Section 3.a.(ii) applies but which relates to products and services in
          addition to Licensed Products and for which an allocation would be
          necessary, the parties shall meet and attempt to agree on which
          portion of the total payments received by AMICUS pursuant to such
          transaction would be subject to this Section 3.a.(ii). If the parties
          cannot agree upon such allocation within a reasonable period of time,
          AMICUS shall select a nationally recognized independent certified
          public accountant, which meets MSSM's approval, to determine such
          allocation. Such allocation shall be determined in accordance with
          generally accepted accounting principles in the United States.

     b.   If AMICUS is required to acquire one or more licenses from third
          parties to make, use or sell a Licensed Product such that aggregate
          royalties payable by AMICUS on Net Sales (including the royalty amount
          due to MSSM pursuant to Section 3.a) exceeds [***], then AMICUS shall
          be entitled to a credit against the royalty payments due to MSSM
          pursuant to Section 3.a equal to [***] of the amount of such excess;
          provided, however, that in no event shall the amount otherwise payable
          to MSSM be reduced to less than [***] of Net Sales.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        5

<PAGE>

     c.   AMICUS shall notify MSSM of the date of the first commercial sale of a
          Licensed Product as soon as practicable after the making of such
          commercial sale.

     d.   Commencing on the date of first commercial sale of a License Product,
          AMICUS shall, within 90 days from the last day of each June and
          December in each Calendar Year during the term of the License, submit
          to MSSM a full and detailed report of royalties or payments due MSSM
          under the terms of this Agreement for the preceding half year (the
          "Semi-Annual Report"), setting forth the Net Sales and lump sum
          payments and all other payments or consideration from sublicensees
          upon which such royalties are computed and including, on a Licensed
          Product-by-Licensed Product basis at least:

          i)   the quantity of Licensed Products used, sold, transferred or
               otherwise disposed of,

          ii)  the selling price of each Licensed Product,

          iii) the deductions permitted to arrive at Net Sales,

          iv)  the royalty computations and deductions therefrom based on
               royalty payments to third parties.

          If no royalties are due, a statement shall be sent to MSSM stating
          such fact. The full amount of any royalties or other payments due to
          MSSM for the preceding half-year shall accompany each such report on
          royalties and payments. AMICUS and all its sub-licensees shall keep
          for a period of at least five years after the date of entry, full,
          accurate and complete books and records consistent with sound business
          and accounting practices and in such form and in such detail as to
          enable the determination of the amounts due to MSSM from AMICUS
          pursuant to terms of this Agreement.

     e.   At the request and expense of MSSM, AMICUS shall permit (and shall
          require its sub-licensees to permit) an independent certified or
          chartered public accountant appointed by MSSM, at reasonable times
          during normal business hours and upon reasonable notice, but in any
          event no more than once per calendar year, to examine the records of
          AMICUS (and its sub-licensees) to the extent necessary to verify
          royalty calculations made hereunder; provided, however, that such
          examination shall be at the expense of AMICUS if it reveals a
          discrepancy in the amount of royalties to be paid in MSSM's favor of
          more than five percent. Results of such examination shall be made
          available to both AMICUS and MSSM.

4.   Method of Payment

     a.   Royalties and any other payments due to MSSM hereunder shall be paid
          to MSSM in United States dollars.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        6

<PAGE>

     b.   AMICUS shall be responsible for prompt payment to MSSM of all
          royalties due on sale, transfer or disposition of Licensed Products by
          the sub-licensees of AMICUS.

     c.   As to sales occurring in currencies other than U.S. Dollars, Net Sales
          shall first be calculated in the currency in which sale occurred and
          then converted to U.S. Dollars at the buying rate for such currency
          calculated as the average of the closing buying rate for the first and
          last business day of the six month period for which royalties are due,
          as set forth in the Wall Street Journal for such dates.

5.   Development and Commercialization

     a.   AMICUS shall use its commercially reasonable efforts to bring one or
          more Licensed Products to market through a thorough, vigorous and
          diligent program for exploitation of the Patent Rights in the Field.
          AMICUS shall not, however, be required to pursue the development of
          more than one Licensed Product at a time, nor shall AMICUS be required
          to pursue every possible Licensed Product.

     b.   Attached as Appendix A to this Agreement is the current development
          plan of AMICUS for the forthcoming period of twelve months (such plan,
          as updated from time to time as described in clause (c) below, the
          "Plan"). As and when appropriate, future Plans will incorporate
          efficacy, pharmaceutical safety, toxicological and/ or clinical tests
          or any other activities necessary in order to obtain the approval of
          the FDA and counterpart foreign regulatory agencies for the
          production, use and sale of Licensed Products, as well as marketing
          plans to commercialize Licensed Products that have obtained such
          approvals.

     c.   On the earlier of thirty (30) days prior to the first anniversary of
          the Effective Date or the end of AMICUS's first fiscal year, and
          thereafter on each successive anniversary of such date, AMICUS shall
          deliver to MSSM a report setting forth in reasonable detail progress
          and problems with the implementation of the Plan and, providing an
          update on its efforts to commercialize Licensed Products, including a
          forecast and schedule of major events required to market the Licensed
          Products. Such report shall also include any amendments proposed by
          AMICUS to the Plan based upon the progress made and then current
          scientific, regulatory and commercial exigencies relating to Licensed
          Products. Within forty-five (45) days following the delivery of such a
          report (a "Diligence Report") representatives of MSSM may request a
          meeting with AMICUS to review the Diligence Report, the status of the
          efforts of AMICUS under the Plan and any proposed amendments to the
          Plan. Any such proposed amendments to the Plan shall be subject to
          approval by MSSM, which approval shall not be unreasonably withheld or
          delayed. Upon approval of any such amendments, they shall be deemed
          amendments to the Plan, added to Appendix A and deemed incorporated
          into this Agreement.

     d.   AMICUS will use its commercially reasonable efforts to accomplish the
          milestones described in the Plan.

     e.   Provided that applicable laws, rules and regulations so require, the
          manufacture of Licensed Products shall be carried out by AMICUS or its
          agents in accordance

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       7

<PAGE>

          with FDA Good Laboratory Practices and FDA Good Manufacturing Practice
          ("GMP") procedures in a facility which has been certified by the FDA
          and the performance of the tests, trials, studies and other activities
          specified in the Plan shall be so performed by AMICUS or its agents in
          accordance with FDA clinical trial procedures. MSSM shall have no
          responsibility for the actual production, distribution, sale or use of
          any Licensed Product.

     f.   If at any time AMICUS abandons or suspends its efforts to
          commercialize all Licensed Products for a period exceeding ninety (90)
          days, AMICUS shall immediately notify MSSM giving reasons and a
          statement of its intended actions. MSSM shall be entitled to terminate
          this Agreement for "Cause" in accordance with Section 11 upon any such
          abandonement.

     g.   MSSM shall also be entitled to terminate this Agreement for "Cause" in
          accordance with Section 11 if AMICUS shall fail to deliver any
          Diligence Report on a timely basis, or fail to use commercially
          reasonable efforts to implement the Plan, and such failure is not
          cured within the sixty (60) day period set by the notice provided
          pursuant to Section 11, unless such failure is excused by:

          i)   causes beyond AMICUS's direct control; or

          ii)  MSSM's failure to meet its obligations hereunder; or

          iii) inaction of any federal or state agency whose approval is
               required for commercial sales of Licensed Products.

     h.   Provided that applicable laws, rules and regulations so require, the
          performance of the tests, trials, studies and other activities
          specified in subsection b, above, shall be carried out in accordance
          with FDA Good Laboratory Practices and FDA Good Manufacturing Practice
          ("GMP") procedures in a facility which has been certified by the FDA
          as complying with GMP. MSSM shall have no responsibility for the
          actual production, distribution, sale or use of any Licensed Product.

6.   Confidential Information.

     a.   In the course of research to be performed under this Agreement, it
          will be necessary for each party to disclose "Confidential
          Information" to the other. For purposes of this Agreement,
          "Confidential Information" is defined as all information, data and
          know-how disclosed by one party (the "Disclosing Party") to the other
          (the "Receiving Party"), either embodied in tangible materials
          (including writings, drawings, graphs, charts, photographs,
          recordings, structures, technical and other information) marked
          "Confidential" or, if initially disclosed orally, which is reduced to
          writing marked "Confidential" within 21 days after initial oral
          disclosure, other than that information which is:

          i)   known by the Receiving Party at the time of its receipt, and not
               through a prior disclosure by the Disclosing Party, as documented
               by the Receiving Party's business records; or

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       8

<PAGE>

          ii)  at the time of disclosure, or thereafter becomes, published or
               otherwise part of the public domain without breach of this
               Agreement by the Receiving Party; or

          iii) obtained from a third party who has the legal right to make such
               disclosure and without any confidentiality obligation to the
               Disclosing Party; or

          iv)  independently developed by the Receiving Party without the use of
               Confidential Information received from the Disclosing Party and
               such independent development can be documented by the Receiving
               Party; or

          v)   disclosed to governmental or other regulatory agencies in order
               to obtain patents, provided that such disclosure may be made only
               to the extent reasonably necessary to obtain such patents or
               authorizations, and further provided that any such patent
               applications shall be filed in accordance with the terms of this
               Agreement; or

          vi)  required by law, regulation, rule, act or order of any
               governmental authority to be disclosed.

     b.   The Receiving Party agrees that at all times and notwithstanding any
          termination, expiration, or cancellation hereunder, it will hold the
          Confidential Information of the Disclosing Party in strict confidence,
          will use all reasonable safeguards to prevent unauthorized disclosure
          by its employees and agents. Notwithstanding the foregoing, the
          parties recognize that industry standards with respect to the
          treatment of Confidential Information may not be appropriate in an
          academic setting. However, MSSM agrees to retain Confidential
          Information of AMICUS in the same manner and with the same level of
          confidentiality as MSSM retains its own Confidential Information.

     c.   The Receiving Party will maintain reasonable procedures to prevent
          accidental or other loss, including unauthorized publication of any
          Confidential Information of the Disclosing Party. The Receiving Party
          will promptly notify the Disclosing Party in the event of any loss or
          unauthorized disclosure of the Confidential Information.

     d.   Upon termination or expiration of this Agreement, and upon written
          request, the Receiving Party will promptly return to the Disclosing
          Party all documents or other tangible materials representing
          Confidential Information and all copies thereof.

     e.   The Receiving Party will immediately notify the Disclosing Party in
          writing, if it is requested by a court order, a governmental agency,
          or any other entity to disclose Confidential Information in the
          Receiving Party's possession. The Disclosing Party will have an
          opportunity to intervene by seeking a protective order or other
          similar order, in order to limit or prevent disclosure of the
          Confidential Information. The Receiving Party will disclose only the
          minimum

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       9

<PAGE>

          Confidential Information required to be disclosed in order to comply,
          whether or not a protective order or other similar order is obtained
          by the Disclosing Party.

7.   Patent Rights.

     a.   If either party to this Agreement acquires information that a third
          party is infringing one or more of the Patent Rights, the party
          acquiring such information shall promptly notify the other party to
          Agreement in writing of such infringement.

     b.   In the event of infringement of the Patent Rights, AMICUS shall have
          the right, but not the obligation, to bring suit against the
          infringer. Should AMICUS elect to bring suit against an infringer,
          AMICUS shall be entitled to retain counsel of its own choosing, and
          shall have the right to join MSSM as party plaintiff in any such suit.
          Except as otherwise provided herein, the expenses of such suit or
          suits that AMICUS elects to bring, shall be paid for entirely by
          AMICUS and AMICUS shall hold MSSM free, clear and harmless from and
          against any and all costs of such litigation, including attorneys'
          fees. AMICUS shall not compromise or settle such litigation without
          the prior written consent of MSSM which shall not be unreasonably
          withheld.

     c.   If AMICUS shall undertake the enforcement or defense of the Patent
          Rights by litigation, AMICUS may withhold royalties otherwise
          thereafter due MSSM hereunder and apply the same toward reimbursement
          of up to half of AMICUS's expenses, including reasonable attorney's
          fees, in connection therewith, provided however that the maximum
          amount that can be withheld each year shall not exceed 50% of
          royalties due to MSSM in that year.

     d.   If AMICUS exercises its right to sue, it shall first reimburse itself
          out of any sums recovered in such suit or in settlement thereof for
          all costs and expenses of every kind and character, including
          reasonable attorneys' fees, necessarily involved in the prosecution of
          any such suit, and if after such reimbursement, any funds shall remain
          from said recovery, the amount of said funds shall be added to the
          amount of Net Sales for the calendar quarter in which such recovery
          was made.

     e.   If AMICUS does not bring suit against said infringer pursuant to
          subsection b, above, or has not commenced negotiations with said
          infringer for discontinuance of said infringement, within 90 days
          after receipt of such notice, MSSM shall have the right, but not the
          obligation, to bring suit for such infringement and to join AMICUS as
          a party plaintiff, in which event MSSM shall hold AMICUS free, clear
          and harmless from and against any and all costs and expenses of such
          litigation, including attorneys' fees. In the event MSSM brings suit
          for infringement of the Patent Rights, MSSM shall have the right to
          first reimburse itself out of any sums recovered in such suit or
          settlement thereof for all costs and expenses of every kind and
          character, including reasonable attorneys' fees necessarily involved
          in the prosecution of such suit, and if after such reimbursement, any
          funds shall remain from said recovery, MSSM shall promptly pay to
          AMICUS an amount equal to 50 percent of such remainder and MSSM
          shall be entitled to receive and retain the balance of the remainder
          of such recovery.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       10

<PAGE>

     f.   Each party shall have the right to be represented by counsel of its
          own selection, at its sole expense, in any suit for infringement of
          the Patent Rights instituted by the other party to this Agreement
          under the terms hereof.

     g.   AMICUS shall cooperate fully with MSSM at the request of MSSM,
          including, by giving testimony and producing documents lawfully
          requested in the course of a suit prosecuted by MSSM for infringement
          of the Patent Rights; provided MSSM shall pay all reasonable expenses
          (including attorneys' fees) incurred by AMICUS in connection with such
          cooperation. MSSM shall cooperate with AMICUS in the prosecution of a
          suit by AMICUS for infringement of the Patent Rights, provided that,
          except as otherwise provided in Section 7.f., AMICUS shall pay all
          reasonable expenses (including attorneys' fees) involved in such
          cooperation.

     h.   AMICUS shall, upon receipt of reasonable documentation, promptly
          reimburse MSSM for all of the reasonable and customary fees and
          expenses incurred by MSSM as of the Effective Date, which the parties
          expect to be approximately $100,000, in the prosecution and
          maintenance of the Patent Rights. In addition, AMICUS will reimburse
          MSSM, within 30 days of the execution of this agreement, for
          $100,000 in total payments to Jian-Qiang Feh and Satoshi Ishii
          pursuant to the letter of agreement dated March 24, 2000 between MSSM
          and Jian-Qiang Feh and Satoshi Ishii.

8.   Patent Prosecution

     a.   MSSM is the owner of the Patent Rights. MSSM has retained Darby and
          Darby, PC to prepare, file, prosecute, and maintain the pending patent
          applications and issued patents comprising the Patent Rights.

     b.   MSSM shall maintain an attorney-client relationship with Darby and
          Darby (or other patent counsel mutually agreed to by both parties
          ("Law Firm")) with respect to the Patent Rights. Nothing in this
          agreement shall prevent Amicus from establishing an attorney client
          relationship with Law Firm, except that nothing herein shall authorize
          or permit Law Firm to take any action for, or on behalf of Amicus that
          would be adverse to MSSM and/or involve a conflict of interest or a
          violation of the Code of Professional Responsibility.

     c.   From and after the Effective Date, Law Firm will interact directly
          with Amicus on all patent prosecution and patent maintenance matters
          related to the Patent Rights. Amicus shall request that the Law Firm
          send to MSSM:

               i) Copies of any document pertaining to the ongoing prosecution
               of the Patent Rights received from the U.S. Patent and Trademark
               Office, within ten (10) business days after such receipt; and

               ii) Copies of any document to be submitted to the U.S. Patent and
               Trademark Office (or any other patent granting authority) in any
               such patents or applications, at least ten (10) business days
               prior to the date

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       11

<PAGE>

               on which such document is mailed to such patent office or
               granting authority and at least twenty (20) days prior to such
               mailing date for responses to Patent Office action for which the
               Patent and Trademark Office accords a response period of more
               than thirty (30) days. Amicus shall request that Law Firm, using
               their professional judgment, accept reasonable changes that MSSM
               communicates to such counsel if such request for changes are
               received by Amicus more than five (5) business days prior to the
               date on which such document is due at the patent granting
               authority. The time limits contained in this Section 8.c.ii shall
               not apply if the application of the time allowed herein would
               create an imminent bar to patentability.

     d.   Prior to abandoning prosecution of any of the Patent Rights (or to
          abandoning any patent) covered by this Agreement, Amicus will:

               i) Notify MSSM of its intention to abandon such patent or
               application(s) at least twenty (20) days prior to the last date
               for taking action to preserve such patent or applications(s);

               ii) Permit Law Firm to continue prosecution and/or maintenance of
               such patent or application at MSSM's sole expense.

     e.   Except as otherwise expressly provided herein, Amicus shall bear all
          costs and fees incurred during the term of this Agreement in
          connection with the filing, maintenance, prosecution, protection and
          the like of the Patent Rights. Law Firm shall invoice AMICUS directly
          for all work relating to the filing, prosecution and maintenance of
          the Patent Rights and shall provide copies of all invoices to MSSM.
          AMICUS will pay invoices directly to Law Firm and copy MSSM on each
          payment.

     f.   If at any time during the term of this Agreement AMICUS decides that
          it is undesirable, as to one or more countries, to prosecute or
          maintain any patents or patent applications within the Patent Rights,
          it shall give prompt written notice thereof to MSSM, and upon receipt
          of such notice AMICUS shall be released from its obligations to bear
          all of the expenses to be incurred thereafter as to such countries in
          conjunction with such patent(s) or patent application(s). MSSM shall
          be free to grant rights in and to the released patent or patent
          applications in such countries to third parties, without further
          notice or obligation to AMICUS, and AMICUS shall have no rights
          whatsoever to exploit the released patents or patent applications in
          such countries.

     g.   Notwithstanding the foregoing, MSSM reserves the absolute right to
          countermand any instruction given by Amicus to Law Firm with respect
          to the Patent Rights.

     h.   Nothing herein contained shall be deemed to be a warranty by MSSM that
          the manufacture, use, or sale of any element of the Patent Rights or
          any Licensed Product will not infringe any patent(s) of a third party.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       12

<PAGE>

9.   Liability and Indemnification.

     a.   AMICUS shall indemnify, defend and hold harmless MSSM and its
          trustees, officers, directors, medical and professional staff,
          employees, students and agents and their respective successors, heirs
          and assigns (the "Indemnitees"), against any liability, damage, loss
          or expense (including reasonable attorneys' fees and expenses of
          litigation) incurred by or imposed upon the Indemnitees or any one of
          them in connection with any claims, suits, actions, demands or
          judgments: (i) arising out of the production, manufacture, sale, use
          in commerce or in human clinical trials, lease, or promotion by AMICUS
          or by a licensee, Affiliate or agent of AMICUS of any Licensed
          Product, process or service relating to, or developed pursuant to,
          this Agreement, or (ii) arising out of any other activities to be
          carried out pursuant to this Agreement.

     b.   AMICUS's indemnification under subsection a(i), above, shall apply to
          any liability, damage, loss or expense whether or not it is
          attributable to the negligent activities of the Indemnitees. AMICUS's
          indemnification under subsection a (ii), above, shall not apply to any
          liability, damage, loss or expense to the extent that it is
          attributable to the negligence, gross negligence or intentional
          misconduct of the Indemnitees.

     c.   AMICUS shall, at its own expense, provide attorneys reasonably
          acceptable to MSSM to defend against any actions brought or filed
          against any party indemnified hereunder with respect to the subject of
          indemnity contained herein, whether or not such actions are rightfully
          brought.

     d.   EXCEPT AS PROVIDED IN THIS SECTION 9, NEITHER PARTY SHALL BE LIABLE TO
          THE OTHER FOR INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR
          PUNITIVE DAMAGES.

10.  Security for Indemnification.

     a.   At such time as any Licensed Product is being commercially distributed
          or sold (other than for the purpose of obtaining regulatory approvals)
          by AMICUS or by a sub-licensee, Affiliate or agent of AMICUS and to
          the extent that it is available on commercially reasonable terms,
          AMICUS shall at its sole cost and expense, procure and maintain
          policies of comprehensive general liability insurance in amounts not
          less than [***] per incident and [***] annual aggregate and naming the
          indemnitees as additional insureds. Such comprehensive general
          liability insurance shall provide (i) product liability coverage and
          (ii) broad form contractual liability coverage for AMICUS's
          indemnification under Section 9 of this Agreement. The minimum amounts
          of insurance coverage required under this Section 10 shall not be
          construed as a limit of AMICUS's liability with respect to its
          indemnification under Section 9 of this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       13

<PAGE>

     b.   AMICUS shall provide MSSM with written evidence of such insurance upon
          request of MSSM. AMICUS shall provide MSSM with written notice at
          least 60 days prior to the cancellation, non-renewal or material
          change in such insurance; if AMICUS does not obtain replacement
          insurance providing comparable coverage within such 60 day period
          effective immediately upon notice to AMICUS, MSSM shall have the right
          to terminate this Agreement effective at the end of such 60 day period
          without notice or any additional waiting periods.

     c.   AMICUS shall maintain such comprehensive general liability insurance
          beyond the expiration or termination of this Agreement during: (i) the
          period that any product, process or service, relating to, or developed
          pursuant to, this Agreement is being commercially distributed or sold
          (other than for the purpose of obtaining regulatory approvals) by
          AMICUS or by a licensee, Affiliate or agent of AMICUS and (ii) a
          reasonable period after the period referred to in (c)(i) above which
          in no event shall be less than seven years.

11.  Term and Termination.

     a.   This Agreement shall come into force as of the Effective Date. Unless
          sooner terminated as provided herein, this Agreement shall expire on
          the expiration of the last to expire of the Patent Rights.

     b.   At any time prior to expiration of the term of this Agreement either
          party may terminate this Agreement forthwith for cause upon notice to
          the other party. "Cause" for termination of this Agreement shall be
          deemed to exist if either MSSM or AMICUS materially breaches or
          defaults in the performance or observance of any of the provisions of
          this Agreement and such breach or default is not cured within 60 days
          or, in the case of failure to pay any amounts due hereunder, 30 days
          (unless otherwise specified herein) after the giving of notice by the
          other party specifying such breach or default, or if either MSSM or
          AMICUS discontinues its business or becomes insolvent or bankrupt.

     c.   Any amount payable hereunder by one of the parties to the other, which
          has not been paid by its due date of payment shall bear interest from
          its due date of payment until the date of actual payment, at the rate
          of two percent per annum in excess of the Prime Rate prevailing at the
          Citibank, Inc., New York, New York, during the period of arrears and
          such amount and the interest thereon may be set off against any amount
          due, whether in terms of this Agreement or otherwise, to the party in
          default by any non-defaulting party.

     d.   Upon termination of this Agreement for any reason, all rights in and
          to the Patent Rights shall revert to MSSM.

     e.   Termination of this Agreement shall not relieve the parties of any
          obligation occurring prior to such termination.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       14

<PAGE>

     f.   Sections 2e., 3e., 6, 9, 10 and 14 hereof shall survive and remain in
          full force and effect after any termination, cancellation or
          expiration of this Agreement.

12.  Representation and Covenants

     a.   MSSM hereby represents, warrants, and covenants to AMICUS that it is a
          corporation duly organized and validly existing under the laws of the
          state or other jurisdiction of its incorporation or formation;

     a.   AMICUS hereby represents, warrants and covenants to the other party
          hereto that it is a corporation duly organized and validly existing
          under the laws of the state or other jurisdiction of its incorporation
          or formation;

     b.   Each of MSSM and AMICUS hereby represents, warrants and covenants to
          the other party hereto as follows:

          i) the execution, delivery and performance of this Agreement by such
          party has been duly authorized by all requisite corporate action;

          ii) it has the power and authority to execute and deliver this
          Agreement and to perform its obligations hereunder;

          iii) the execution, delivery and performance by such party of this
          Agreement and its compliance with the terms and provisions hereof is
          not prohibited and does not and will result in a breach of any of the
          terms and provisions of, or constitute a default under, (i) a loan
          agreement, guaranty, financing agreement, agreement affecting a
          product, or other agreement or instrument binding or affecting it or
          its property; (ii) the provisions of its charter documents or bylaws;
          or (iii) any order, writ, injunction or decree of any court or
          governmental authority entered against it or by which any of its
          property is bound;

          iv) the execution, delivery and performance of this Agreement by such
          party does not require the consent, approval, or authorization of, or
          notice, declaration, filing or registration with, any governmental or
          regulatory authority, and the execution, delivery or performance of
          this Agreement will not violate any law, rule or regulation applicable
          to such party;

          v) this Agreement has been duly authorized, executed and delivered and
          constitutes such party's legal, valid and binding obligation
          enforceable against it in accordance with its terms subject, as to
          enforcement, to bankruptcy, insolvency, reorganization and other laws
          of general applicability relating to or affecting creditors' rights
          and to the availability of particular remedies under general equity
          principles; and

          vi) it shall comply with all applicable material laws and regulations
          relating to its activities under this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       15

<PAGE>

          vii) Each party represents that performance of all the terms of this
               Agreement will not breach any agreement to keep in confidence
               proprietary information acquired by a party prior to the
               execution of this Agreement.

     c.   Except as otherwise expressly provided herein, MSSM hereby represents,
          warrants and covenants to AMICUS that:

          i)   MSSM has the full right, power and authority to grant all of the
               right, title and interest in the License; and

          ii)  there are no judgments or settlements against or owed by MSSM, or
               any pending or threatened claims or litigation relating to MSSM's
               interest in the Patent Rights; and

          iii) MSSM has not granted to any other party any rights that would
               conflict with the rights granted in this Agreement.

13.  Assignment.

     Neither party shall have the right to assign, delegate or transfer at any
     time to any party, in whole or in part, any or all of the rights, duties
     and interest herein granted without first obtaining the written consent of
     the other party to such assignment, such consent not to be unreasonably
     withheld; provided, however, that AMICUS may, with thirty (30) days prior
     written notice to MSSM, assign its rights and delegate its duties under the
     Agreement to the purchaser of substantially all of the assets of AMICUS,
     provided that the assignee agrees in writing to be bound by all the terms
     and conditions of this Agreement.

14.  Use of Name.

     Neither party may use the name of the other or its Affiliates in any
     publicity or advertising. A party may issue a press release or otherwise
     publicize or disclose this Agreement or the confidential terms and
     conditions hereof only with the prior written consent of the other party.

15.  Miscellaneous.

     a.   In carrying out this Agreement the parties shall comply with all
          local, state and federal laws and regulations including but not
          limited to, the provisions of Title 35 U.S.C.A. Section 200 et seq.
          and 15 CFR Section 368 et seq.

     b.   If any provision of this Agreement is determined to be invalid or
          void, the remaining provisions shall remain in effect.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       16

<PAGE>

     c.   This Agreement shall be deemed to have been made in the State of New
          York and shall be governed and interpreted in all respects under the
          laws of the State of New York. Any and all disputes hereunder shall be
          brought and resolved solely in the courts of the State of New York in
          and for the Borough of Manhattan.

     d.   All payments or notices required or permitted to be given under this
          agreement shall be given in writing and shall be effective when either
          personally delivered or deposited, postage prepaid, in the United
          States registered or certified mail, addressed as follows:

          To MSSM:   Mount Sinai School of Medicine of New York University
                     Attention: W. Patrick McGrath, Ph.D.
                     One Gustave L. Levy Place
                     New York, New York 10029-6574

          Copy to:   General Counsel (at the same address)

          To AMICUS: Amicus Therapeutics, Inc.
                     c/o Collinson Howe & Lennox, LLC
                     1055 Washington Blvd.
                     Stamford, CT 06901
                     Attention: Gregory Weinhoff, MD

          or such other address or addresses as either party may hereafter
          specify by written notice to the other. Such notices and
          communications shall be deemed to have been received by the addresses
          on the date of delivery if personally delivered or 14 days after
          having been sent by registered mail.

     e.   This Agreement and the exhibits attached hereto constitute the entire
          Agreement between the parties with respect to the subject matter
          hereof and no variations, modification or waiver of any of the terms
          or conditions hereof shall be deemed valid unless made in writing and
          signed by both parties hereto. This Agreement supersedes any and all
          prior agreements or understandings, whether oral or written, between
          AMICUS and MSSM.

     f.   No waiver by either party of any non-performance or violation by the
          other party of any of the covenants, obligations or agreements of such
          other party hereunder shall be deemed to be a waiver of any subsequent
          violation or non-performance of the same or any other covenant,
          agreement or obligation, nor shall forbearance by any party be deemed
          to be a waiver by such party of its rights or remedies with respect to
          such violation or non-performance.

     g.   The descriptive headings contained in this Agreement are included for
          convenience and reference only and shall not be held to expand, modify
          or aid in the interpretation, construction or meaning of this
          Agreement.

     h.   It is not the intent of the parties to create a partnership or joint
          venture or to assume partnership responsibility or liability. The
          obligations of the parties shall

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       17

<PAGE>

          be limited to those set out herein and such obligations shall be
          several and not joint.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date first above written.

MOUNT SINAI SCHOOL OF MEDICINE          AMICUS THERAPEUTICS, INC.
OF NEW YORK UNIVERSITY

By:  /s/ Nathan Kase                    By:  /s/ Gregory Weinhoff
    ---------------------------------       ------------------------------------
Name:  Nathan Kase, M.D.                Name: Gregory M. Weinhoff
      -------------------------------
Title:  Interim Dean                    Title: Chief Executive Officer
       ------------------------------
Date:  4-15-02                          Date: April 15, 2002
      -------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       18

<PAGE>

                         AMENDMENT TO LICENSE AGREEMENT
                              DATED APRIL 15, 2002
                                     BETWEEN
                    MOUNT SINAI SCHOOL OF NEW YORK UNIVERSITY
                          AND AMICUS THERAPEUTICS INC.

Whereas the Mount Sinai School of Medicine of New York University (MSSM) and
Amicus Therapeutics Inc. (AMICUS) desire to make amendments to the License
Agreement between the two parties dated April 15, 2002.

NOW THEREFORE, IT IS HEREBY DECLARED AND AGREED BETWEEN THE PARTIES THAT THE
FOLLOWING AMENDMENTS TO THE LICENSE AGREEMENT BE EFFECTIVE AS OF ______________:

1. Under Section 1 (Definitions) the definition of "Patent Rights" shall be
amended to the following:

     i.   "Patent Rights" shall mean any issued patent or any patent to be
          issued pursuant to any United States or foreign patent application
          owned, by MSSM, listed in this subclause 1.i.(i)-(v) together with any
          continuations in whole or in part, divisional or substitute patents,
          any reissues or re-examinations of any such application or patents,
          and any extension of the term of any such patent in the Field. The
          issued patents and patent applications referred to in the preceding
          sentence are:

               i) U.S. Pat. No. 6,274,597-"Method of Enhancing Lysosomal
               AlphaGalA";

               ii) U.S. Pat. Applic. No. 09/604,053 (continuation in part)-
               "Method of Enhancing Mutant enzyme activities in lysosomal
               storage disease";

               iii) U.S. Pat. Applic. No. 09/926,285 (continuation of the '597
               Patent; and

               iv) U.S. Pat. Applic. No. 09/948,348 (continuation of the '053
               CIP Application.

               v) U.S. Pat. Applic. entitled "Screen for active site specific
               chaperones for enhancing protein folding of mutant proteins"
               filed on February 28, 2003.

               vi) US provisional patent application entitled "Combination
               Therapy For Treating Protein Deficiencies( )" filed on January
               31, 2003

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
<PAGE>

               vii) US provisional patent application entitled "Combination
               Therapy For Treating Protein Deficiencies" filed on February 18,
               2003

All other terms and conditions of the License Agreement remain unchanged and in
full force and effect.

MOUNT SINAI SCHOOL OF MEDICINE          AMICUS THERAPEUTICS, INC.
OF NEW YORK UNIVERSITY

By: /s/ Kenneth L. Davis                By: /s/ Norman Hardman
    ---------------------------------       ------------------------------------
Name: Kenneth L. Davis, M.D.            Name: Norman Hardman, Ph.D.
Title: Dean                             Title: President and CEO

Date: 3-13-03                           Date: 4.8.2003

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
<PAGE>
                                                                  Execution Copy

                         MOUNT SINAI SCHOOL OF MEDICINE
                 One Gustave L. Levy Place, New York, NY 10029

April 8, 2004

Amicus Therapeutics, Inc.
675 U.S. Highway One
North Brunswick, NJ 08902

Re:  Agreement between Mount Sinai School of Medicine of New York University
     ("MSSM") and Amicus Therapeutics, Inc. ("AMICUS") dated as of April 15,
     2002 (the "License Agreement)

Gentlemen:

This will confirm the agreement and understanding between MSSM and AMICUS
regarding an amendment to the License Agreement as follows:

1.   The definition of "Conformational Diseases" contained in Section 1.d. of
     the License Agreement is hereby amended in its entirety to read as follows:

     "Conformational Diseases" shall mean any inherited or acquired human
disease in which at least a sub-population of the affected individuals have one
or more mutant proteins that results in impaired protein folding, stability,
degradation or sorting. Examples of Conformational Diseases include lysosomal
story diseases (including Fabry and Gaucher), Cystic Fibrosis, Long QT Syndrome,
Diabetes Insipidus, and Hypogonadism.

2.   The definition of "Field" contained in Section 1.e. of the License
     Agreement is hereby amended in its entirety to read as follows:

                         [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
                         WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
                         SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
                         SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
                         24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT
                         OF 1934, AS AMENDED
<PAGE>
Amicus Therapeutics, Inc.
April 8, 2004
Page 2

     "Field" shall mean the discovery, validation, development, application,
     production or sale of Licensed Products: (i) for the prevention, diagnosis
     and treatment of Conformational Diseases (ii) that are Chaperones to
     improve the production and/or manufacturing of therapeutic proteins for the
     treatment of Conformational Diseases which are therapeutic proteins
     manufactured and sold by third parties, (iii) that are Chaperones
     discovered and developed by AMICUS to improve the production and/or
     manufacturing of therapeutic proteins for the treatment of diseases other
     than Conformational Diseases which are therapeutic proteins manufactured
     and sold by third parties, or (iv) that are Chaperones discovered and
     developed by Amicus for administration with therapeutic proteins or gene
     therapy constructs for the treatment of diseases other than Conformational
     Diseases which gene therapy constructs or therapeutic proteins are
     manufactured and sold by third parties.

3.   Section 2.c ii) of the License Agreement is hereby amended in its entirety
     to read as follows:

     2.c. ii)  the sub-license shall not be assignable, in whole or in part;
               provided, however, that the sublicensee may, written notice to
               MSSM, assign the sub-license in connection with a merger or
               acquisition of the sub-licensee or the sale by the sublicensee of
               substantially all of its assets;

4.   Section 13 of the License Agreement is hereby amended in its entirety to
     read as follows:

     Neither party shall have the right to assign, delegate or transfer at any
     time to any party, in whole or in part, any or all of the rights, duties
     and interest herein granted without first obtaining the written consent of
     the other party to such assignment, such consent not to be unreasonably
     withheld; provided, however, that AMICUS may, with written notice to MSSM,
     assign its rights and delegate its duties under the Agreement to a
     successor in interest of AMICUS by virtue of merger or acquisition or to
     the purchaser of substantially all of the assets of AMICUS, provided that
     the assignee agrees in writing to be bound by all the terms and conditions
     of this Agreement.

5.   MSSM hereby confirms that "Contract Signature Payments" and "Third Party
     Milestone Payments" as such terms are used in the License Agreement
     excludes (i) payment or reimbursement for patent expenses incurred by
     AMICUS, (ii) payment or reimbursement for the costs of research or
     development conducted by AMICUS that is sponsored by third parties or (iii)
     purchases by third parties of AMICUS securities.

6.   Except as expressly modified by this Amendment, all terms and conditions of
     the License Agreement shall remain in full force and effect.

                         [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
                         WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
                         SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
                         SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
                         24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT
                         OF 1934, AS AMENDED

<PAGE>
Amicus Therapeutics, Inc.
April 8, 2004
Page 3

Please indicate your acceptance of and agreement with the foregoing in the space
provided below.

Very truly yours,

Mount Sinai School of Medicine
of New York University

By:  Kenneth L. Davis
     ------------------------
     Name: Kenneth L. Davis, M.D.
     Title: Dean

ACCEPTED AND AGREED

Amicus Therapeutics, Inc.

By:  /s/ Norman Hardman
     ------------------------
     Name: Norman Hardman
     Title: CEO

                         [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
                         WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
                         SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
                         SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
                         24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT
                         OF 1934, AS AMENDED

<PAGE>
                       AMENDMENT #3 TO LICENSE AGREEMENT

                              DATED APRIL 15, 2002

                                    BETWEEN

             MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY

                                      AND

                           AMICUS THERAPEUTICS, INC.

Whereas, on April 15, 2002, the Mount Sinai School of Medicine of New York
University (MSSM) and Amicus Therapeutics, Inc. (AMICUS) entered into that
certain License Agreement attached hereto as Annex "A";

Whereas, on April 1, 2003, the parties entered into that certain Amendment
attached hereto as Annex "B"; and

Whereas, on April 8, 2004, the parties entered into that certain Amendment
attached hereto as Annex "C";

NOW THEREFORE, IT IS HEREBY DECLARED AND AGREED BETWEEN THE PARTIES THAT THE
FOLLOWING AMENDMENTS TO THE LICENSE AGREEMENT BE EFFECTIVE AS OF OCTOBER 25,
2006:

1.   The definition of "Chaperone" in Section 1c is hereby deleted and
     Section 1c shall be left blank intentionally.

2.   The definition of "Conformational Diseases" in Section 1d shall be amended
     and restated to read in its entirety as follows:

     d.   "Conformational Diseases" shall mean any inherited or acquired human
          disease in which affected individuals have at least one mutant allele
          that results in impaired protein folding, stability, degradation, or
          sorting of the encoded mutant protein.

3.   The definition of "Field" in section 1e shall be amended and restated to
     read in its entirety as follows:

     e.   "Field" shall mean the discovery, validation, development,
          application, production or sale of Licensed Products for the
          prevention, diagnosis and treatment of all human indications,
          diseases and conditions.

4.   Under Section 1 (Definitions) the definition of "Patent Rights" shall be
     amended and restated to read in its entirety as follows:

                 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED
                 AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
                 REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
               FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
                  PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
                  SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
<PAGE>

i.   "Patent Rights" shall mean any issued patent or any patent application
     owned by MSSM, listed in this subclause 1(i)-(xiii), together with any
     continuations in whole or in part, divisional, or substitute patents, any
     reissues or re-examinations of any such application or patents, any foreign
     counterparts of any such application or patents, and any extension of the
     term of any such patent in the Field. The issued patents and patent
     applications referred to in the preceding sentence are:

     i)    U.S. Pat. No. 6,274,597-"Method of Enhancing Lysosomal
           Alpha-Galactosidase A"

     ii)   U.S. Pat. No. 6,583,158 (continuation-in-part)-"Method of Enhancing
           Mutant Enzyme Activities in Lysosomal Storage Disorders"

     iii)  U.S. Pat No. 6,744,135 (continuation of the '597 patent)-"Method of
           Enhancing Lysosomal Alpha-Galactosidase A"

     iv)   U.S. Pat. No. 6,599,919 (continuation of the '053 CIP application)-
           "Method of Enhancing Mutant Enzyme Activities in Lysosomal Storage
           Diseases"

     v)    U.S. Pat. No. 6,589,964 (continuation of the '919 patent)-"Method of
           Enhancing Mutant Enzyme Activities in Lysosomal Storage Diseases"

     vi.   U.S. Pat. No. 6,916,829 (continuation of the '919 patent)-"Method of
           Enhancing Mutant Enzyme Activity in Gaucher Disease"

     vii)  U.S. Pat. Applic. No. 10/868,133 (continuation of '135 patent)-
           "Method of Enhancing Lysosomal AlphaGalA"

     viii) Allowed U.S. Pat. Applic. No. 10/989,258 (continuation of the 829
           patent)-"Method for Enhancing Mutant Enzyme Activities in Gaucher
           Disease"

     ix)   U.S. Pat. Applic. No. 11/264,672 (continuation of the '258
           application)-"Method for Enhancing Mutant Protein Activity"

     x)    U.S. Pat. Applic. No. 10/377,179-"Screen for Active Site-Specific
           Chaperones for Enhancing Protein Folding of Mutant Proteins"

     xi)   U.S. Pat. Applic. No. 10/781,356-"Combination Therapy for Treating
           Protein Deficiencies"

     xii)  U.S. Pat. Applic. No. 11/317,404-"Stable Formulations of Purified
           Protein"

                                       2

                 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED
                 AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
                 REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
               FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
                  PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
                  SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

<PAGE>
5. Section 2c(iii) shall be amended and restated in its entirety as follows:

   iii) the sub-licensee shall be entitled to grant further sub-licenses,
        provided that the sub-licensee complies with the obligations of AMICUS
        under this Section 2c, Section 2d and all other provisions of this
        Agreement relating to sub-licenses by AMICUS;

6. Section 3.a. shall be amended and restated in its entirety as follows:

   In consideration of the grant of the License hereunder, subject to the
   provisions of Section 3b, AMICUS shall pay to MSSM a royalty of (a) [***]
   percent [***] on Net Sales of Core Licensed Products and (b) [***] percent
   [***] on Net Sales of Non-Core Licensed Products. If AMICUS grants
   sublicenses with respect to any Licensed Product pursuant to which AMICUS
   receives any Non-Royalty Remuneration, then AMICUS shall pay to MSSM:

     (i) [***] of Non-Royalty Remuneration in connection with any Core Licensed
         Product;

     (ii) [***] of Non-Royalty Remuneration in connection with any Non-Core
          Licensed Product which relates to any of the conditions, indications
          or diseases listed on Schedule I to this Amendment No. 3;

     (iii) [***] of Non-Royalty Remuneration in connection with any Non-Core
           Licensed Product (other than (ii) above) where the pertinent
           sublicense occurs after three (3) years from the date of this
           Amendment No. 3; and

     (iv) [***] of Non-Royalty Remuneration in connection with any Non-Core
          Licensed Product (other than (ii) above) where the pertinent
          sublicense occurs within three (3) years from the date of this
          Amendment No. 3.

   As used in this Section 3:

   "Contract Signature Payment" means license initiation fees and other up-front
   payments made to AMICUS in connection with a sublicense or other similar
   arrangement;

   "Core Licensed Product" shall mean any Licensed Product: (i) for the
   treatment of Conformational Diseases, including, but not limited to, Licensed
   Products used as monotherapy for Conformational Diseases and Licensed
   Products used in combination therapy with exogenously administered
   therapeutic proteins for Conformation Diseases; (ii) discovered and developed
   by Amicus for use in combination therapy with exogenously administered
   therapeutic proteins or gene constructs for the treatment of diseases other
   than Conformational Diseases; (iii)

                                       3

[***] INDICATED MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
<PAGE>
     addressing the production, formulation, or storage of therapeutic proteins
     manufactured by third parties for the treatment of Conformational Diseases
     and (iv) discovered and developed by Amicus to address the production,
     formulation, or storage of therapeutic proteins manufactured by third
     parties for the treatment of diseases other than Conformational Diseases.

     "Maintenance Fees" means payments (such as annual minimum royalties) made
     by sublicensees to AMICUS to preserve, or to avoid a forfeiture of rights
     under, the sublicense agreement;

     "Non-Core Licensed Product" shall mean any Licensed Product other than a
     Core Licensed Product. Non-Core Licensed Products include, but are not
     limited to, Licensed Products which are not for the treatment of
     Conformational Diseases, but are administered to increase the activity of
     endogenous wide-type proteins;

     "Non-Royalty Remuneration" means all remuneration, other than royalties,
     received by AMICUS, including, but not limited to, Contract Signature
     Payments, Third Party Milestone Payments and Maintenance Fees, but
     excludes:

            (i)  payment or reimbursement for patent expenses incurred by
                 AMICUS;

           (ii)  payment or reimbursement for the costs of research or
                 development conducted by AMICUS that is sponsored by third
                 parties; or

          (iii)  purchases by third parties of AMICUS securities; and

     "Third Party Milestone Payments" means payments made to AMICUS upon
     fulfillment by AMICUS or the sublicense of designated development
     objectives or regulatory requirements.

     With respect to any sublicensing or other transaction to which this Section
     3. applies but which relates to products and services in addition to
     Licensed Products and for which an allocation would be necessary, the
     parties shall meet and attempt to agree on which portion of the total
     payments received by AMICUS pursuant to such transaction would be subject
     to this Section 3.. If the parties cannot agree to such allocation within a
     reasonable period of time, AMICUS shall select a nationally recognized
     independent certified public accountant, which meets MSSM's approval, to
     determine such allocation. Such allocation shall be governed by generally
     accepted accounting principles in the United States.

7.   Section 3.b. shall be amended and restated in its entirety as follows:

     If AMICUS is required to acquire one or more licenses from third parties to
     make, use or sell a Licensed Product such that aggregate royalties payable
     by AMICUS

                                       4

                    [***] INDICATES MATERIAL THAT HAS BEEN OMITTED
                    AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
                    REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
                    FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
                    PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
                    SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

<PAGE>
     on Net Sales (including the royalty due to MSSM pursuant to Section 3.a)
     exceeds [***] percent [***], then AMICUS shall be entitled to a credit
     against the royalty payments due to MSSM pursuant to Section 3.a equal to
     [***] percent [***] of the amount of such excess; provided, however, that
     in no event shall the amount otherwise payable to MSSM be reduced to less
     than [***] percent [***] of Net Sales.

8.   Except as expressly modified by this Amendment, all terms and conditions of
     the License Agreement shall remain in full force and effect.

MOUNT SINAI SCHOOL OF MEDICINE               AMICUS THERAPEUTICS, INC.
OF NEW YORK UNIVERSITY

By:    /s/ Kenneth L. Davis                  By:    /s/ Donald J. Hayden
       ----------------------                       --------------------

Name:  Kenneth L. Davis, M.D.                Name:  Donald J. Hayden
       ----------------------

Title: Dean                                  Title: Interim President and CEO
       ----------------------

Date: Oct 25, 2006                           Date:  10/24/06
      -----------------------                       --------------------

                                        5

                    [***] INDICATES MATERIAL THAT HAS BEEN OMITTED
                    AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
                    REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
                    FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
                    PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
                    SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
<PAGE>
                                   SCHEDULE I

                           NON-CORE LICENSED PRODUCTS

i. NEUROLOGICAL DISORDERS:

    -  Neurological disorders and their corresponding wild-type protein targets:

          -  Parkinson's disease and glucocerebrosidase;

               Parkinson's disease shall include (i) any pre-Parkinson's
               condition in which there is, or is the potential for,
               (alpha)-synuclein accumulation; (ii) diagnosed Parkinson's; and
               (iii) any other condition associated with
               (alpha)-synucleinopathies or abnormal presence or amount of
               (alpha)-synuclein.

          -  Niemann-Pick Type C Disease and glucocerebrosidase;

          -  Alzheimer's disease and (alpha)-secretase; and

          -  Alzheimer's Disease and Pin1.

               Alzheimer's Disease shall (i) any pre-Alzheimer's condition in
               which there is, or is the potential for (Beta)-amyloid
               accumulation; (ii) treatment of diagnosed Alzheimer's; and (iii)
               any other condition associated (Beta)-amyloidoses or or abnormal
               presence or amount of (Beta)-amyloid.

ii. CANCER:

     -  Cancer and Phosphotase and Tensin Homolog (PTEN).

               Cancer shall include (i) any pre-cancerous condition in which
               there is the potential for cancer to develop, including but not
               limited to Cowden disease and Bannayan-Zonana Syndrome; (ii)
               diagnosed cancer; and (iii) any other cancer that would benefit
               from increased activity of PTEN.

iii.  CARDIOVASCULAR DISEASE:

     -  Hyperlipidemia and lipoprotein lipase.

               a.  Hyperlipidemia includes (i) any pre-condition in which there
                   is the potential for hyperlipidemia to develop; (ii) any
                   condition in which hyperlipidemia is manifest.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
<PAGE>
THE INDICATIONS COVERED BY THE NON-CORE LICENSED PRODUCTS INCLUDE NON-
CORE INDICATIONS FALLING INTO THE FOLLOWING CATEGORIES:

a.   Individuals having no mutated proteins but in whom it would be beneficial
     to increase the activity of specific wild-type proteins which are already
     expressed.

     i.   e.g. glucocerebrosidase in Parkinson's patients who do not have any
          mutant alleles

     ii.  glucocerebrosidase in Niemann-Pick Type C in patients who do not have
          any mutant alleles

b.   Individuals having heterozygous, non-conformational mutations (i.e., on one
     allele), resulting in decreased levels of a protein, who would benefit by
     increasing activity of the protein expressed from the wild-type allele.

     i.   e.g., Parkinson's in patients have a mutation in GCase on one allele,
          but which mutation is not a "conformational mutation" and where the
          patients do not have Gaucher disease

                                       7
                 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED
                 AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
                 REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
               FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
                  PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
                  SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]